Language
English
Publication Date
6-23-2023
Journal
Science Advances
DOI
10.1126/sciadv.adg0188
PMID
37352342
PMCID
PMC10289659
PubMedCentral® Posted Date
6-23-2023
PubMedCentral® Full Text Version
Post-print
Abstract
Evolution of antibiotic resistance is a world health crisis, fueled by new mutations. Drugs to slow mutagenesis could, as cotherapies, prolong the shelf-life of antibiotics, yet evolution-slowing drugs and drug targets have been underexplored and ineffective. Here, we used a network-based strategy to identify drugs that block hubs of fluoroquinolone antibiotic-induced mutagenesis. We identify a U.S. Food and Drug Administration- and European Medicines Agency-approved drug, dequalinium chloride (DEQ), that inhibits activation of the
Keywords
Animals, Mice, Pharmaceutical Preparations, Mutagenesis, Mutation, Escherichia coli, Anti-Bacterial Agents, Drug Resistance, Microbial
Published Open-Access
yes
Recommended Citation
Zhai, Yin; Pribis, John P; Dooling, Sean W; et al., "Drugging Evolution of Antibiotic Resistance at a Regulatory Network Hub" (2023). Faculty and Staff Publications. 2188.
https://digitalcommons.library.tmc.edu/baylor_docs/2188
Included in
Biological Phenomena, Cell Phenomena, and Immunity Commons, Biomedical Informatics Commons, Genetics and Genomics Commons, Medical Genetics Commons, Medical Molecular Biology Commons, Medical Specialties Commons